A hero dose of science.

Prior to co-founding Circadian Wellness, Alex was the Co Founder and VP of Business Development for Shopcbd.com - the largest cbd e-com platform in North America - responsible for the company’s sales and operations, including end-to-end management of supply chain, sales activities, and service and support in the market. He brings over 12 years of experience in sales and business development within regulated industries and refined his time in cannabis , alcohol and liquor sales & marketing. He also co-founded Cannara Biotech, Quebec’s largest Indoor Cannabis company, and played a key role in raising over $60 million in cannabis space IPOs. Alex is an accomplished business leader and biohacking enthusiast recognized for his ability to build key relationships.

Jeff is a seasoned entrepreneur with active roles in vibrant and diverse businesses including co-founder and advisor to Mountain Valley MD and business development advisor to Beattie’s Distilleries. Jeff has founded numerous innovative enterprises and is a season adviser across the global medicinal cannabis market. Jeff has extensive plant knowledge and business expertise across the health and wellness industry with a recent focus on functional mushroom based nutraceutical products. Jeff is a co-founder of Circadian Wellness.

Lynn Marie Morski, MD, JD, is president of the Psychedelic Medicine Association, host of the Plant Medicine Podcast, Director of Medical Affairs for Mydelica, founder of Plant Medicine.org, and the medical director for Way of Leaf.com. 
Dr. Morski received her medical degree from St. Louis University School of Medicine, did family medicine residency at Mayo Clinic, and completed a sports medicine fellowship at the University of Arizona. She received her law degree from Thomas Jefferson School of Law and is a member of the California Bar.

Dr. Ingmar Gorman is a psychologist who specializes in assisting populations who have had experiences with psychedelics and other psychoactive compounds. He is the Director of the Psychedelic Education and Continuing Care Program at the Center for Optimal Living, where he leads groups, workshops, and works with individual clients. Additionally, Dr. Gorman has extensive training in treating substance misuse, drawing upon mentorship by Dr. Andrew Tatarsky and Dr. Jen Talley, in Harm Reduction Psychotherapy and Mindfulness based approaches. Dr. Gorman received his PhD in clinical psychology from the New School for Social Research. He completed his internship at Bellevue Hospital Center and is currently an NIH funded postdoctoral fellow at New York University's Behavioral Sciences Training in Drug Abuse Research Program (BST), which is NIDA’s largest and longest-standing training program. Dr. Gorman is also site co-principal investigator and therapist on a Phase 3 clinical trial studying the potential psychotherapeutic utility of MDMA for post-traumatic stress disorder.

Madison Margolin is the co-founder and editorial director of DoubleBlind, a media company and education platform at the forefront of the rapidly growing psychedelic movement. As a working journalist based between New York and Los Angeles, Margolin has covered psychedelics, cannabis, drug policy, Jewish culture, and spirituality for a variety of publications including Playboy Magazine, Rolling Stone, Nylon, VICE, LA Weekly, Tablet, and was featured in High Times among other outlets. A graduate of Columbia Journalism School and UC Berkeley, Margolin has traveled everywhere from pot farms in the Emerald Triangle to the shores of the Ganges River, and all over Israel-Palestine, exploring the role of plant medicine in religion, mental health, and conflict resolution. She got her start in journalism with a column on cannabis at the Village Voice, after having lived in south Tel Aviv working with Eritrean refugees. With more than 6 years of experience covering cannabis and psychedelics, Madison has spoken on topics like social equity, cannabis feminism, drug journalism, and so forth at conferences like SXSW, Horizons: Perspectives in Psychedelics, Digital Hollywood, the Association of Alternative New Media, the American Society of Journalists and Authors, Pepperdine's Cannabis Law Symposium, and more. You can find her on Twitter, Instagram and LinkedIn.

David E. Nichols PhD previously held the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and in addition was a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue University College of Pharmacy. He was continuously funded by the NIH for nearly three decades and served on numerous government review panels. His two principal research areas focused on drugs that affect serotonin and dopamine transmission in the CNS. He began medicinal chemistry research on hallucinogens in 1969 and has been internationally recognized as a top expert on the medicinal chemistry of psychedelics (hallucinogens). He has published more than 300 scientific articles, book chapters, and monographs. In 1993 he founded the Heffter Research Institute, which has supported and funded clinical research with psilocybin and led the so-called “renaissance in psychedelic research.”

Cosmo is a drug development entrepreneur dedicated to unlocking the medical potential of psychoactive substances, such as cannabis and psychedelics, in order to help patients in need. He is a founder and CEO of Beckley Psytech, a private company established in 2019 to address neurological and psychiatric disorders through psychedelic medicine.
Prior to Beckley Psytech, Cosmo worked closely with the Beckley Foundation for over 10 years and, in 2016, he co-founded Beckley Research & Innovations to develop ethical business models built around promising scientific research into medical cannabis and psychedelics. Cosmo subsequently served as Co-Founder and Managing Director of Beckley Canopy Therapeutics, a cannabis-based drug development company, and Spectrum Biomedical UK, a medical cannabis distribution company. Both of these companies were acquired in 2019 by Canopy Growth Corporation, the world’s largest medical cannabis company. Cosmo received a Double First-Class degree from Oxford University and has previously directed two feature documentaries on Netflix about international drug policy and the history of psychedelic use in America.

Dr Ben Sessa is chief medical officer at Awakn Life Sciences, a biotechnology company with clinical operations researching, developing, and delivering psychedelic medicine to treat addiction. As a consultant child and adolescent psychiatrist, Dr Sessa has worked with young people and adults in the field of addictions and trauma-related psychiatry for over 20 years. He has a particular interest in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. Over the last 15 years, Dr Sessa has been part of many ground-breaking scientific and clinical studies administering psychedelic compounds to augment psychotherapy. He has recently completed research with Imperial College London exploring the world’s first MDMA-assisted therapy trial for the treatment of Alcohol Use Disorder and continues to carry out research in this area. Dr Sessa is also an experienced medical cannabis prescriber. Dr Sessa is widely published in the academic and popular press in respect of the field of medical psychedelics. He has written several academic books, notably The Psychedelic Renaissance (2012/2017).Dr Sessa is a trained MDMA and psilocybin therapist and has delivered keynote talks at international conferences in the psychedelic community for 15+ years.

Richard Knowles, Ph.D. is the founder and executive director of Delos Psyche Research Group as well as a licensed psychologist working at a psychiatry and psychotherapy clinic in the San Francisco Bay Area. He’s also served as faculty at Sofia University, teaching classes on psychology and consciousness studies at the doctoral level. As a researcher, his topics of inquiry include consciousness studies, altered states of consciousness, psychedelic studies, and exceptional human experience. He has additionally worked for the Multidisciplinary Association of Psychedelic Studies as a lead adherence rater for their MDMA-assisted psychotherapy research treating PTSD along with having received the MAPS therapy training. He is proud to serve as principal investigator of an LSD microdosing study, and clinical trials using infusions of 5-MeO-DMT and looks forward to conducting a wide variety of psychedelic research in the future. He is also one of the founding members of Mind Tech Therapeutics, a Canadian psychedelics company promising to bring highest quality psychedelics products to the market, starting in Canada.

Chris was the founder & CEO of Edgewood Health Network, the largest private network of residential/outpatient treatment providers in Canada. He led the merger and acquisition of Canada’s top 3 treatment centres to form Canada’s largest entity of treatment centres and outpatient clinics

Former National Director of Edgewood Health Network; leading 10 outpatient centers. Andrew was the former VP at GreeneStone Muskoka, an International Certified Alcohol and Drug Counsellor and has 14 years working directly for the NHL/NHLPA Substance Abuse Program.

David is the CEO and Founder of Maya and a Director at Unlimited Sciences. Previously, David was Co-founder & CPO at Baker Technologies, which he exited after achieving a valuation of $250MM. David graduated summa cum laude in Architecture from Cambridge University and built a nonprofit to help Kenyan children access schooling. Brought up in Papua New Guinea, Portugal and Scotland, he began his career in New York with Daniel Libeskind, working on the Ground Zero masterplan. He has a decade of experience designing consumer software and his interests are behavioral data, digital art, user experience design, oil painting, and mindfulness.

Believing that you should never hesitate to trade your cow for a handful of magic beans, Ronan has built a career out of doing things that others say can't be done. Ronan started his career as a securities lawyer at Blake, Cassels & Graydon LLP but left after realizing he was much too creative for the profession of law. Since then, Ronan has helped launch business across a number of industries from gold, to cannabis, and, most recently, in psychedelics where he is a Co-founder and the Executive Chairman of Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP), a global leader in the development of psychedelic therapies. When not being thoroughly incorrigible, Ronan lives in Toronto with his wife and two children.

Matthew is the Susan Hill Ward Endowed Professor of Psychedelics and Consciousness Research at Johns Hopkins University School of Medicine. Working with psychedelics since 2004, he is one of the world’s most widely published experts on psychedelics. Matt published psychedelic safety guidelines in 2008, helping to resurrect human psychedelic research. He published the first research on psychedelic treatment of tobacco addiction in 2014, and the largest study of psilocybin in cancer distress in 2016. His 2018 psilocybin review recommended Schedule IV upon potential medical approval. Matt also conducts behavioral economic research on the psychology of addiction and sexual risk. He is a past President of the Psychopharmacology and Substance Abuse Division of the American Psychological Association, and current President of the International Society for Research on Psychedelics. He has been widely interviewed about drugs and addiction, including by Anderson Cooper on 60 Minutes, the New York Times, the Washington Post, the Wall Street Journal, the BBC, CNN, Fox Business News, NPR, and was featured in Michael Pollan’s book How to Change Your Mind.

Mendel s the founder and CEO of Wavepaths, a startup building the world´s first AI person-centred music solution for psychedelic therapies. Prior to this, he worked as a PhD and postdoctoral neuroscientist at Imperial College London since 2012, where his research was the first to demonstrate music’s central role in psychedelic therapies. He is a thought leader on the therapeutic use of music and publishes and speaks frequently on this topic. He has been featured in Nature News, San Francisco Chronicles, Vice Motherboard, Rolling Stone, The Guardian, TEDx, a.o.. Mendel lives and works on planet Earth, and in his spare time likes to get into nature, and out of his mind with his musical instruments.

Shelby is the Co-Founder and CEO of DoubleBlind, a media company at the forefront of the psychedelic movement. Her work has appeared in VICE, Playboy, Quartz, LA Weekly, the Huffington Post, Thrillist, and Rolling Stone, among others. Shelby worked in broadcast news production for CBS News, covering presidential elections, protests, natural disasters, and other breaking news. Spurred by a passion for print, she transitioned to magazine writing, working as an editor at Pasadena Magazine and receiving her Master’s Degree in long-form journalism from Columbia University in 2015. Since then, Shelby has worked as a columnist at LA Weekly and an editor at Herb, with extensive features on post-traumatic stress disorder in the veteran community, the cannabis industry, psychedelics and mysticism, and the psychedelic research boom. Shelby has spoken and written on topics like psychedelics in the media, the ethics of mainstreaming psychedelics, and others at SXSW, Horizons: Perspectives in Psychedelics, Harvard Law School, and more. In 2020, she was named by Forbes as a female leader in cannabis and psychedelics.

James Fadiman earned his BA from Harvard and his MA and PhD from Stanford. He has held a variety of teaching, consulting, training, counseling and editorial positions. He has served on a number of for profit and non-profit companies and taught in psychology departments, and design engineering. He has published textbooks, professional books, a self-help book, a novel, and a series of videos, Drugs: the children are choosing, for National Public Television. He has been involved in psychedelic research for more than fifty years, the last ten years uncovering and researching the multiple uses of microdosing. His book, The Psychedelic Explorer’s Guide: Safe, Therapeutic and Sacred Journeys was written to help individuals benefit from careful guided trips, and introduced the first modern uses of microdosing, His most recent book with Jordan Gruber), Your Symphony of Selves: Discover and Learn More of Who We Are contains ideas and tools critical for successful integration and self-understanding. He continues to research and consult about low-cost, high-benefit uses of psychedelics with a number of emerging psychedelics-oriented companies.

As Senior Director of Strategic Partnerships, Tura builds upon her background in strategic planning and business development in leading the cultivation and management of strategic partnerships for Usona Institute. Tura engages directly in identifying and fostering key relationships with research collaborators, donors, and drug development and consultant partners to ensure streamlined and well-managed alignment with Usona’s clinical program goals, early commercialization planning, and new research initiatives.Prior to Usona, Tura worked as a business development consultant with specialization in strategic planning, development of new markets and services, sustainable design, and global engagement for high-technology, non-profit, academic, and professional service organizations. Within that role, Tura applied her expertise in facilitation, creative thinking, and organizational development to position clients through innovative partnerships and new collaboration opportunities.Tura has bachelor’s and master’s degrees in International Economic and Commercial Relations and Scandinavian Studies from the University of Wisconsin-Madison, and is a LEED Accredited Professional. She also serves on advisory boards for Nikean Foundation, Synthesis Institute, and the Global Initiative for Psychedelic Science Economics at UCSF.

Charles is the Director of Clinical and Translational Research at Usona Institute. He is also the Mary Sue and Mike Shannon Chair for Healthy Minds, Children & Families and Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin–Madison. Prior to this he was Professor in the Department of Psychiatry, College of Medicine, and the Barry and Janet Lang Professor of Integrative Mental Health at the Norton School of Family and Consumer Sciences, College of Agriculture and Life Sciences, University of Arizona.In addition to his academic positions, Dr. Raison serves as the founding Director of the Center for Compassion Studies in the College of Social and Behavioral Sciences at the University of Arizona and is the mental health expert for CNN.com. Dr. Raison has an undergraduate degree in anthropology from Stanford University and a Master’s degree in English literature from the University of Denver.He received his medical degree from Washington University School of Medicine in St. Louis, MO and did his residency training in psychiatry at the Semel Institute for Neuroscience and Human Behavior at UCLA, where he later served as Director of Emergency Psychiatry Services. Dr. Raison is internationally recognized for his studies examining novel mechanisms involved in the development and treatment of major depression and other stress-related emotional and physical conditions, as well as for his work examining the physical and behavioral effects of compassion training.The recipient of several teaching awards, Dr. Raison has received research funding from the National Institute of Mental Health, National Center for Complementary and Alternative Medicine, and the Centers for Disease Control and Prevention. Dr. Raison received the Raymond Pearl Memorial Award from the Human Biology Association “in recognition of his contributions to our understanding of evolutionary biocultural origins of mental health and illness,” and was recently recognized as one of five university-wide “Faculty of Excellence” at the University of Wisconsin–Madison.

Emma is a psychiatrist, psychotherapist and psychedelic researcher based at the University Health Network (UHN) in Toronto. She is also on faculty at the University of Toronto. She started her career as an attending psychiatrist in the women's program at the Centre for Addiction and Mental Health. Her specialty is women's mental health and the treatment of developmental trauma, sexual trauma and complex PTSD. She has extensive training in multiple modalities of psychotherapy and has worked clinically with ketamine-assisted psychotherapy. She also has a growing interest in psychosocial oncology. Dr. Hapke works with MAPS as the principal investigator for the Montreal site of the phase 3 study examining MDMA-assisted psychotherapy for PTSD and is MAPS-trained to deliver MDMA-assisted psychotherapy. In the Spring of 2021, Dr. Hapke joined UHN as an attending psychiatrist and is the co-founder and associate director of the Nikean Psychedelic Psychotherapy Research Centre.

Daniel is an attending psychiatrist at the University Health Network (UHN) as well as the Inner City Health Associates (ICHA) in Toronto, Canada and he is a clinical lecturer in the Department of Psychiatry at the University of Toronto. He works on an Assertive Community Treatment Team, serving people with severe and persistent mental illnesses (SPMI), as well as the Palliative Education and Care for the Homeless (PEACH) team through ICHA. Dr. Rosenbaum is interested in psychosocial oncology and palliative care, especially end-of-life issues for marginalized populations. Dr. Rosenbaum is a certified CALM therapist (Managing Cancer and Living Meaningfully) and has received training in ketamine-assisted psychotherapy (KAP). He is a trainee in the fall 2021 cohort of the MAPS MDMA Therapy Training Program. Dr. Rosenbaum has published articles in peer-reviewed journals on psychedelic-assisted therapy in palliative and cancer care and on psychedelic microdosing. He is a co-founder and faculty member of the Nikean Psychedelic Psychotherapy Research Centre at UHN.

Hardi has been an entrepreneur for the last 16 years, in the fields of agriculture, sales, retail, IT, and mycology. He has studied Economics at Tartu University and cultivations of medicinal and gourmet mushrooms at Mycelia laboratory in Belgium. In 2019, Hardi successfully established the world's biggest Chaga mushroom (Inonotus obliquus) plantations in Baltic and Nordic countries.Since 2016 he has been actively following the fields of psychedelics and psychotherapy. Right now he is establishing the world's first one-of-a-kind psychedelic experience center called Inlibrium in Amsterdam, Netherlands. Inlibriums' mission is to give an option to explore a psychedelic experience in a safe and modern environment. Inlibrium is not a clinic or a shamanic retreat. Inlibrium is the doorway to psychedelic experience and inner liberation in a modern, but cozy and safe environment, under the supervision of experienced practitioners. For more information follow Hardi on LinkedIn and visit inlibrium.com.

Having joined the ibogaine legalization movement in 1993, Noah was an early crossover between the psychedelic sector and the broader drug policy reform population. In 2008 he organized the first public discussion of the ongoing severe racial disproportion in New York City cannabis arrests, the issue that served as the basis for the campaign to legalize cannabis in New York. In 2010 he coined the term "psychedelic law" when he founded his blog, New Amsterdam Psychedelic Law, to describe the type of legal analysis that is necessary to effectuate psychedelic policy change. He has served as the lead organizer of the historic New York City Cannabis Parade, deconstructed the DEA’s legal theory for maintaining permanent cannabis prohibition, and assisted the Decriminalize Denver campaign in getting Board of Elections approval for the text of the psilocybin decriminalization initiative. In July 2020 he began organizing a legislative campaign for psychedelic law reform in New York. He provides consulting services with a niche focus on New York City.

Dr. Charles Nichols is a Professor of Pharmacology at LSU Health Sciences Center in New Orleans and has been researching psychedelics for 24 years. He earned his B.S. at Purdue University, his Ph.D. at Carnegie Mellon University studying the developmental genetics of fruit fly eye and retina development, and performed his postdoctoral work at Vanderbilt University School of Medicine in the Department of Pharmacology researching serotonin 5-HT2 receptor neuropharmacology under the mentorship of Dr. Elaine Sanders-Bush. His research centers on the pharmacology of serotonin 5-HT2A receptors, and he and his laboratory have made several key discoveries throughout the years. These include the first study of the effects of psychedelics on gene expression in brain, identification of specific populations of cell types within the brain that directly respond to psychedelics, the development of animal experimental systems that recapitulate the long-lasting antidepressant effects of psilocybin for mechanistic study, and discovery of the potent and profound anti-inflammatory effects of psychedelics for potential treatment of diseases like asthma and cardiovascular disease, among others. He is a founding member of the International Society for Research on Psychedelics, and its current President-Elect. Charles is also scientific co-founder of Eleusis Therapeutics, which is dedicated to unlocking the full potential of psychedelics both in and beyond psychiatry.

Anthony Rossi is the CEO of Force One Marketing, Force One Capital and QQ20 Fund Inc., a capital advisory and investor relations firm in Toronto, Ontario. Anthony's firm focuses on investing in early stage companies in tech, health, psychedelics and real estate through his venture fund. Force One is backed by a number of large family offices, banks and influential financiers who work very closely on all financial transactions.  Last year, Force One’s  psychedelic investments alone returned over 1300% annually (holdings are north of $45M today).
​
2020 - He was named to the Top 100 Canadian professionals by Canadian Entrepreneur Magazine
2016 - Ernst and Young Entrepreneur of the year Nominee
2012 - Top 30 under 30 award by the "Who's who of business"

Previously, the CEO of Andromeda Entertainment, where he oversaw the distribution of VR experiences that provide psycho-spiritual fulfillment through embodiment and meditation. As a game designer, Robin is recognized as an early maverick of Virtual Reality, for leveraging the medium to provoke psychedelic brain states. His work and ideas are featured in Netflix’s Screenland docu-series, and the documentary Game Loading: Rise of the Indies.